- IXICO, the brain health company, is to take part in a new collaborative pan-European research effort under the Innovative Medicines Initiative's (IMI) umbrella focused on addressing the challenges of successfully delivering therapies to people with Alzheimer's disease (AD). In this collaboration with leading pharmaceutical companies and academics, IXICO is receiving €100k of funding to undertake data aggregation and analysis using its digital technology platforms.

The platforms will be used to devise clinically meaningful measurements from biosensors worn by patients, and to develop enhanced models of disease progression to help select the most appropriate treatment for an individual patient.

Within ROADMAP, IXICO will demonstrate how both approaches can be deployed in real-world settings, leveraging IXICO's existing activities in the Cygnus real world evidence (RWE) study (

Story provided by